Management of marked liver enzyme increase during clozapine treatment: A case report and review of the literature

International Journal of Psychiatry in Medicine

Volumn 34, Issue 1, 2004, Pages 83-89

  Erdogan, Ayten ^a,b   Kocabasoglu, Nese ^a   Yalug, Irem ^a   Ozbay, Gulsen ^a   Senturk, Hakan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Atypical antipsychotics; Clozapine; Hepatotoxicity; Schizophrenia

Indexed keywords

AMINOTRANSFERASE; CLOZAPINE; LIVER ENZYME; NEUROLEPTIC AGENT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG DOSE REDUCTION; HUMAN; LIVER TOXICITY; MALE; REVIEW; SCHIZOPHRENIA;

ADULT; ALANINE TRANSAMINASE; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG MONITORING; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LIVER; MALE; SCHIZOPHRENIA;

EID: 3042616606     PISSN: 00912174     EISSN: None     Source Type: Journal    
DOI: 10.2190/44WA-WXF7-3UHA-FDV1     Document Type: Review

References (21)

1. Kane JM, Honigfeld G, Singer J, Meltzer H. Clozapine in treatment-resistant schizophrenics. Psychopharmacology Bulletin 1988;24(1):62-67.
2. Narendran R, Young CM, Pristach CA, Pato MT, Valenti AM, Fass AR. Efficacy of clozapine in the treatment of atypical antipsychotic refractory schizophrenia: A pilot study. Journal of Clinical Psychopharmacology 2003;23(1):103-104.
3. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane JM. Clinical effects of clozapine in chronic schizophrenia: Response to treatment and predictors of outcome. American Journal of Psychiatry 1994 Dec;151(12):1744-1752.
4. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden D, Schoenfeld DA, Goff DC. Clozapine, diabetes mellitus, weight gain and lipid abnormalities: A five-year naturalistic study. American Journal of Psychiatry 2000;157(6):975-981.
5. Serrano-Duenas M. Atypical antipsychotics: Clozapine-related cardiac complications. Movement Disorders 2000 Nov;15(6):1300.
6. Hummer M, Kurz M, Kurtzhaler I, Oberbauer H, Miller C, Fleischhacker WW. Hepatotoxicity of clozapine. Journal of Clinical Psychopharmacology 1997;17:314-317.
7. Macfarlane B, Davies S, Mannan K, Sarsam R, Pariente D, Dooley J. Fatal acute fulminant liver failure due to clozapine: A case report and review of clozapine-induced hepatotoxicity. Gastroenterology 1997;112(5):1707-1709.
8. Hovens JE, Vogtlander LM, Verhoeve HA, Thunnisen PL. Liver cell necrosis during administration of clozapine. Ned Tijdschr Geneeskd 1994;138(7):363-365.
9. Thatcher GW, Cates M, Blair B. Clozapine induced toxic hepatitis. American Journal of Psychiatry 1995;152:296-297.
10. Worrall R, Wilson A, Cullen M. Dystonia and drug-induced hepatitis in a patient treated with clozapine. American Journal of Psychiatry 1995;152:647-648.
11. Dorta G, Siebenmann R, Frohli P, Koelz HR. Clozapine-induced cholestatic jaundice: A case report. Z Gastroenterology 1989;27(7):388-390.
12. Lammert F, Matern S. Hepatic diseases caused by drugs. Schweiz Rundsch Med Prax 1997;86(29-30):1167-1171.
13. Kellner M, Wiedemann K, Kreig JC, Berg PA. Toxic hepatitis by clozapine treatment. American Journal of Psychiatry 1993;150(6):985-986.
14. Schmidt G, Borsch G, Muller KM, Ricken D. Clozapine induced cholestatic liver lesions. A case study. Deutsch Med Wochenschr 1987;112:844-846.
15. Eggert AE, Crismon ML, Dorson PG, Taylor RL. Clozapine rechallenge after marked liver enzyme elevation (letter). Journal of Clinical Psychopharmacology 1994;14:425-426.
16. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV) (4th ed.). Washington, DC: American Psychiatric Association Publications Division, 1994:273-289.
17. Mouradian-Stamatiadis L, Dumortier G, Januel D, Delmas BA, Cabaret W. Liver function tests during treatment with antipsychotic drugs: A case series of 23 patients. Prog Neuropsychopharmacol Biol Psychiatry 2002;26(7-8):1409-1411.
18. Gaertner I, Altendorf K, Batra A, Gaertner HJ. Relevance of liver enzyme elevations with four different neuroleptics: A retrospective review of 7,263 treatment courses. Journal of Clinical Psychopharmacology 2001;21(2):215-222.
19. Lewis JH. Drug-induced liver disease. Medical Clinics of North America 2000;84(5):1275-1311.
20. Dumotier G, Cabaret W, Stamatiais L, Saba G, Benadriha R, Rocamora JF, Aubriot-Delmas B, Glikman J, Januel D. Hepatic tolerance of atypical antipsychotic drugs. Encephale 2002;28(6):542-551.
21. Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic V. The side-effects of clozapine: A four year follow-up study. Progress of Neuropsychopharmacology and Biologic Psychiatry 1994;18:537-544.